Subtle Medical gets patent for SubtleGAD

By staff writers

May 6, 2021 -- The U.S. Patent and Trademark Office issued a patent to Subtle Medical for its software application SubtleGAD that aims to significantly reduce gadolinium dosage during imaging procedures.

‌The company was issued U.S.‌ ‌patent‌ ‌No.‌ ‌10,997,716‌ for SubtleGAD, which is said to reduce the gadolinium dosage by 90% while maintaining high-quality diagnostic MRI images. Currently in the investigational phase, the software uses proprietary deep-learning algorithms to achieve equivalent diagnostic image quality using only 10% of the gadolinium contrast dose.

‌Subtle‌ ‌Medical‌ ‌claims‌ ‌that‌ ‌‌SubtleGAD‌ ‌can‌ ‌reduce‌ ‌gadolinium‌ ‌dosage‌ ‌by‌ ‌90%.‌
‌Subtle‌ ‌Medical‌ ‌claims‌ ‌that‌ ‌‌SubtleGAD‌ ‌can‌ ‌reduce‌ ‌gadolinium dosage by‌ ‌90%.‌ ‌Image‌ ‌courtesy‌ ‌of‌ ‌Subtle‌ ‌Medical.‌

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking